FindTrial
Sign In

Low intensity pulsed ultrasound on neutropenia induced by chemoradiotherapy in Patients with solid tumor

Low intensity pulsed ultrasound on neutropenia induced by chemoradiotherapy in Patients with solid tumor

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018865
Enrollment
Unknown
Registered
2018-10-14
Start date
2018-10-20
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

Group 1:low intensity pulsed ultrasound (LIPUS):underwent 20 minutes of daily ultrasound treatment at femoral metaphysis for 7 days(0.2 W/cm2, 0.6 MHz)
Group 2:received LIPUS sham treatment.
Group 3:LIPUS+G-CSF. LIPUS: underwent 20 minutes of daily ultrasound treatment at femoral metaphysis for 7 days (0.2 W/cm2, 0.6 MHz). G-CSF: Recombinant Human Granulocyte Colony Stimulating Factor (rh
Group 4:G-CSF CSF: Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF), subcutaneous infection, 5µg/kg/d, Continue until ANC recovery to normal
Group 5:LIPUS: underwent 20 minutes of daily ultrasound treatment at femoral metaphysis for 7 day (0.2 W/cm2, 0.6 MHz)

Sponsors

College of Biomedical Engineering, Chongqing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Part1 1. Male or female patients aged 18-65 years; 2. Absolute value of neutrophil 1.0x10^9/L; 3. The estimated survival time > 6 months; 4. Karnofsky score =60; 5. Sign the inform consent form with good compliance. Part 2 1. Male or female patients, aged 18-75 years; 2. Absolute value of neutrophil 6 months; 4. Karnofsky score =60; 5. Sign the inform consent form with good compliance. Part3 1. Male or female patients, aged 18-75 years; 2. Absolute value of neutrophil 6 months; 4. Karnofsky score =60; 5. Sign the inform consent form with good compliance.

Exclusion criteria

Exclusion criteria: 1. Patients with severe dysfunction of heart, lung, liver and kidney; 2. Patients with severe infection and dystrophy; 3. Patients with diseases of the blood system and immune system; 4. Patients with bone metastasis and bone marrow invasion; 5. Patient used drugs that affect bone marrow function,such as chloramphenicol sulfonamide, amphotericin B, amantadine, etc.

Design outcomes

Primary

MeasureTime frame
Blood cells counting;—

Secondary

MeasureTime frame
Toxic effects;—

Countries

China

Contacts

Public ContactJin-Yun Chen

College of Biomedical Engineering, Chongqing Medical University

chenjinyun2006@126.com+86 13668029697

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026